# Study of Longidaze in the Prevention & Treatment of Pulmonary Fibrosis, Interstitial Lung Diseases Caused by COVID-19

> **NCT04645368** · — · COMPLETED · sponsor: **NPO Petrovax** · enrollment: 160 (actual)

## Conditions studied

- Fibroses, Pulmonary

## Interventions

- **DRUG:** bovhyaluronidase azoxymer

## Key facts

- **NCT ID:** NCT04645368
- **Lead sponsor:** NPO Petrovax
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2022-04-20
- **Final completion:** 2022-04-20
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04645368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04645368, "Study of Longidaze in the Prevention & Treatment of Pulmonary Fibrosis, Interstitial Lung Diseases Caused by COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04645368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*